The Asia Pacific Rare Diseases Treatment Market is expected to witness market growth of 12.9% CAGR during the forecast period (2022-2028).
Many unprecedented opportunities are expected to turn scientific discoveries into efficient treatments for a large number of people living with rare diseases in the United States. Despite these advances in science, more than 90% of rare diseases remain untreatable. New data & genetics technologies have resulted in the development of the first truly transformative new treatments for a small number of rare diseases.
Due to this, it is required to move more quickly so that no disease or patient is left behind in terms of access to safe & effective therapeutics. The scientific landscape for rare diseases is changing rapidly, and this trend is expected to continue. Rare disease patients are increasingly going to benefit from innovative therapeutics, some of which are the result of breakthrough medical technologies.
While rare diseases are uncommon in and of themselves, they are estimated to affect a large number of people in the United States or one out of every ten Americans. The majority of rare diseases are fatal or severely disabling to children. Because of this significant unmet need, it is critical to find ways to accelerate the therapy development process so that the healthcare sector could address many patients and families who are looking for better treatments for rare diseases.
Asia Pacific region is increasing rare disease treatment offerings as a result of significant unmet medical needs and an increase in the prevalence of rare diseases such as rare cancer, rare cardiovascular problems, and infectious diseases. Because of their large populations and better management in response to the spread of COVID-19, countries in the region have benefited from the advantages of investing in rare disease treatments. A large urban population and an increase in diagnostic services is expected to continue in the Asia-Pacific region for future years. As a result, hospital admissions may increase, and more data will be collected.
The China market dominated the Asia Pacific Rare Diseases Treatment Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $21,241.5 million by 2028. The Japan market is poised to grow at a CAGR of 12.3% during (2022 - 2028). Additionally, The India market is experiencing a CAGR of 13.6% during (2022 - 2028).
Based on Distribution Channel, the market is segmented into Specialty Pharmacy, Hospital Pharmacy, and Online Pharmacy. Based on Route of Administration, the market is segmented into Injectable, Oral, and Others. Based on Therapeutic Area, the market is segmented into Cancer, Cardiovascular Conditions, Infectious Diseases, Musculoskeletal Conditions, Endocrine Disorders, Metabolic Disorders, Hematologic Disorders, Neurological Conditions, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Merck Group, Bristol Myers Squibb Company, Pfizer, Inc., AstraZeneca PLC, Takeda Pharmaceutical Company Limited and PTC Therapeutics, Inc.
Many unprecedented opportunities are expected to turn scientific discoveries into efficient treatments for a large number of people living with rare diseases in the United States. Despite these advances in science, more than 90% of rare diseases remain untreatable. New data & genetics technologies have resulted in the development of the first truly transformative new treatments for a small number of rare diseases.
Due to this, it is required to move more quickly so that no disease or patient is left behind in terms of access to safe & effective therapeutics. The scientific landscape for rare diseases is changing rapidly, and this trend is expected to continue. Rare disease patients are increasingly going to benefit from innovative therapeutics, some of which are the result of breakthrough medical technologies.
While rare diseases are uncommon in and of themselves, they are estimated to affect a large number of people in the United States or one out of every ten Americans. The majority of rare diseases are fatal or severely disabling to children. Because of this significant unmet need, it is critical to find ways to accelerate the therapy development process so that the healthcare sector could address many patients and families who are looking for better treatments for rare diseases.
Asia Pacific region is increasing rare disease treatment offerings as a result of significant unmet medical needs and an increase in the prevalence of rare diseases such as rare cancer, rare cardiovascular problems, and infectious diseases. Because of their large populations and better management in response to the spread of COVID-19, countries in the region have benefited from the advantages of investing in rare disease treatments. A large urban population and an increase in diagnostic services is expected to continue in the Asia-Pacific region for future years. As a result, hospital admissions may increase, and more data will be collected.
The China market dominated the Asia Pacific Rare Diseases Treatment Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $21,241.5 million by 2028. The Japan market is poised to grow at a CAGR of 12.3% during (2022 - 2028). Additionally, The India market is experiencing a CAGR of 13.6% during (2022 - 2028).
Based on Distribution Channel, the market is segmented into Specialty Pharmacy, Hospital Pharmacy, and Online Pharmacy. Based on Route of Administration, the market is segmented into Injectable, Oral, and Others. Based on Therapeutic Area, the market is segmented into Cancer, Cardiovascular Conditions, Infectious Diseases, Musculoskeletal Conditions, Endocrine Disorders, Metabolic Disorders, Hematologic Disorders, Neurological Conditions, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Merck Group, Bristol Myers Squibb Company, Pfizer, Inc., AstraZeneca PLC, Takeda Pharmaceutical Company Limited and PTC Therapeutics, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Drug Type- Biologics
- Biosimilar
- Small Molecule
- Specialty Pharmacy
- Hospital Pharmacy
- Online Pharmacy
- Injectable
- Oral
- Others
- Cancer
- Cardiovascular Conditions
- Infectious Diseases
- Musculoskeletal Conditions
- Endocrine Disorders
- Metabolic Disorders
- Hematologic Disorders
- Neurological Conditions
- Others
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- AbbVie, Inc.
- F. Hoffmann-La Roche Ltd.
- Bayer AG
- Novartis AG
- Merck Group
- Bristol Myers Squibb Company
- Pfizer, Inc.
- AstraZeneca PLC
- Takeda Pharmaceutical Company Limited
- PTC Therapeutics, Inc.
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. Asia Pacific Rare Diseases Treatment Market by Drug Type
Chapter 5. Asia Pacific Rare Diseases Treatment Market by Distribution Channel
Chapter 6. Asia Pacific Rare Diseases Treatment Market by Route of Administration
Chapter 7. Asia Pacific Rare Diseases Treatment Market by Therapeutic Area
Chapter 8. Asia Pacific Rare Diseases Treatment Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- AbbVie, Inc.
- F. Hoffmann-La Roche Ltd.
- Bayer AG
- Novartis AG
- Merck Group
- Bristol Myers Squibb Company
- Pfizer, Inc.
- AstraZeneca PLC
- Takeda Pharmaceutical Company Limited
- PTC Therapeutics, Inc.
Methodology
LOADING...
